Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013;35(1):3-9.
doi: 10.1155/2013/510402. Epub 2013 Jul 21.

Biomarkers in schizophrenia: a brief conceptual consideration

Cynthia S Weickert  1 , Thomas W Weickert, Anil Pillai, Peter F Buckley
Affiliations
Review

Biomarkers in schizophrenia: a brief conceptual consideration

Cynthia S Weickert et al. Dis Markers. 2013.

Abstract

Biomarkers have been sought after in the field of schizophrenia research for decades. In this paper, we discuss some of the concepts around developing biomarkers in an effort to understand why the use of biomarkers for schizophrenia has not been realized. In particular, we address the following 4 questions. Why would we need a diagnostic biomarker for schizophrenia? How is a biomarker typically defined and how does that influence the discovery of biomarkers in schizophrenia? What is the best use of biomarkers in schizophrenia? Do any biomarkers for schizophrenia currently exist? Thus, while we suggest that no biomarker currently exists for schizophrenia, the heterogeneity associated with schizophrenia will most likely need to be taken into account which will result in multiple biomarkers that identify the multiple underlying pathophysiological processes involved in schizophrenia. Therefore, much additional work will be required prior to obtaining any well-established biomarkers for schizophrenia.

PubMed Disclaimer

References

    1. Takesada M, Miyamoto E, Kakimoto Y, Sano I, Kaneko Z. Phenolic and indole amines in the urine of schizophrenics. Nature. 1965;207(5002):1199–1200. - PubMed
    1. Bahn S, Noll R, Barnes A, Schwarz E, Guest PC. Challenges of introducing new biomarker products for neuropsychiatric disorders into the market. International Review of Neurobiology. 2011;101:299–327. - PubMed
    1. Kupfer DJ, Regier DA. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. The American Journal of Psychiatry. 2011;168(7):672–674. - PubMed
    1. Fischer BA, Carpenter WT., Jr. Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology. 2009;34(9):2081–2087. - PMC - PubMed
    1. McGorry PD, Nelson B, Goldstone S, Yung AR. Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Canadian Journal of Psychiatry. 2010;55(8):486–497. - PubMed